Biogen presents new two-year data from Phase 2 CELIA study of diranersen
Biogen reported a 38% slowing of decline at two years on CDR-SB with the lowest dose of diranersen, up from 26% at 18 months. No new safety signals were reported for that dose.
Primary source
Company press release (PR Newswire), November 18, 2026
New Diranersen Data at CTAD Mark Continued Progress Toward Combination Therapies for Alzheimer's, Says the ADDF
Read the source: New Diranersen Data at CTAD Mark Continued Progress Toward Combination Therapies for Alzheimer's, Says the ADDF prnewswire.com
Machine-summarized from the source above; not independently reported. How we use automation